3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
1
ZRSEF Quote, Financials, Valuation and Earnings
Last price:
$20.17
Seasonality move
:
9.32%
Day range:
$20.17 - $20.17
52-week range:
$20.17 - $108.05
Dividend yield:
0%
P/E ratio:
11.59x
P/S ratio:
0.21x
P/B ratio:
0.58x
Volume:
80
Avg. volume:
3
1-year change:
-73.4%
Market cap:
$259.8M
Revenue:
$1.1B
EPS (TTM):
-$9.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZRSEF
DocMorris AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$633.2K | -$0.22 | -96.14% | -284.28% | $10.25 |
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$7.8M | -$1.21 | -96.15% | -0.36% | $84.63 |
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -33.3% | $10.51 |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZRSEF
DocMorris AG
|
$20.17 | -- | $259.8M | 11.59x | $0.00 | 0% | 0.21x |
|
ACIU
AC Immune SA
|
$2.98 | $10.25 | $294.9M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.98 | $30.00 | $8.5M | -- | $0.00 | 0% | 14.74x |
|
CRSP
CRISPR Therapeutics AG
|
$42.43 | $84.63 | $3.6B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$5.06 | $10.51 | $186.2M | -- | $0.00 | 0% | 24.55x |
|
NLSP
NLS Pharmaceutics
|
$2.09 | -- | $8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZRSEF
DocMorris AG
|
48.41% | 2.180 | 37.13% | 1.37x |
|
ACIU
AC Immune SA
|
-- | 5.710 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 3.160 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 3.448 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 2.282 | -- | 14.08x |
|
NLSP
NLS Pharmaceutics
|
-- | 2.905 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZRSEF
DocMorris AG
|
-- | -- | -12.11% | -21.68% | -- | -- |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
DocMorris AG vs. Competitors
-
Which has Higher Returns ZRSEF or ACIU?
AC Immune SA has a net margin of -- compared to DocMorris AG's net margin of 21.59%. DocMorris AG's return on equity of -21.68% beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris AG-- -- $861.7M ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About ZRSEF or ACIU?
DocMorris AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $10.25 which suggests that it could grow by 243.81%. Given that AC Immune SA has higher upside potential than DocMorris AG, analysts believe AC Immune SA is more attractive than DocMorris AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris AG0 0 0 ACIUAC Immune SA3 0 0 -
Is ZRSEF or ACIU More Risky?
DocMorris AG has a beta of 0.064, which suggesting that the stock is 93.601% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.294, suggesting its more volatile than the S&P 500 by 29.428%.
-
Which is a Better Dividend Stock ZRSEF or ACIU?
DocMorris AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or ACIU?
DocMorris AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $29.5M. DocMorris AG's net income of -- is lower than AC Immune SA's net income of $6.4M. Notably, DocMorris AG's price-to-earnings ratio is 11.59x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris AG is 0.21x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris AG0.21x 11.59x -- -- ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns ZRSEF or ADXN?
Addex Therapeutics has a net margin of -- compared to DocMorris AG's net margin of -2841.85%. DocMorris AG's return on equity of -21.68% beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris AG-- -- $861.7M ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About ZRSEF or ADXN?
DocMorris AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 275.94%. Given that Addex Therapeutics has higher upside potential than DocMorris AG, analysts believe Addex Therapeutics is more attractive than DocMorris AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris AG0 0 0 ADXNAddex Therapeutics0 0 0 -
Is ZRSEF or ADXN More Risky?
DocMorris AG has a beta of 0.064, which suggesting that the stock is 93.601% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZRSEF or ADXN?
DocMorris AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or ADXN?
DocMorris AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. DocMorris AG's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, DocMorris AG's price-to-earnings ratio is 11.59x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris AG is 0.21x versus 14.74x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris AG0.21x 11.59x -- -- ADXNAddex Therapeutics14.74x -- $62.3K -$1.8M
-
Which has Higher Returns ZRSEF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to DocMorris AG's net margin of --. DocMorris AG's return on equity of -21.68% beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris AG-- -- $861.7M CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About ZRSEF or CRSP?
DocMorris AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.63 which suggests that it could grow by 99.45%. Given that CRISPR Therapeutics AG has higher upside potential than DocMorris AG, analysts believe CRISPR Therapeutics AG is more attractive than DocMorris AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris AG0 0 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is ZRSEF or CRSP More Risky?
DocMorris AG has a beta of 0.064, which suggesting that the stock is 93.601% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.
-
Which is a Better Dividend Stock ZRSEF or CRSP?
DocMorris AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or CRSP?
DocMorris AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. DocMorris AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$85.9M. Notably, DocMorris AG's price-to-earnings ratio is 11.59x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris AG is 0.21x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris AG0.21x 11.59x -- -- CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns ZRSEF or MOLN?
Molecular Partners AG has a net margin of -- compared to DocMorris AG's net margin of -2408.81%. DocMorris AG's return on equity of -21.68% beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris AG-- -- $861.7M MOLNMolecular Partners AG-- -$0.57 $165M -
What do Analysts Say About ZRSEF or MOLN?
DocMorris AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Molecular Partners AG has an analysts' consensus of $10.51 which suggests that it could grow by 107.99%. Given that Molecular Partners AG has higher upside potential than DocMorris AG, analysts believe Molecular Partners AG is more attractive than DocMorris AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris AG0 0 0 MOLNMolecular Partners AG2 1 0 -
Is ZRSEF or MOLN More Risky?
DocMorris AG has a beta of 0.064, which suggesting that the stock is 93.601% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZRSEF or MOLN?
DocMorris AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris AG pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or MOLN?
DocMorris AG quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. DocMorris AG's net income of -- is lower than Molecular Partners AG's net income of -$19M. Notably, DocMorris AG's price-to-earnings ratio is 11.59x while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris AG is 0.21x versus 24.55x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris AG0.21x 11.59x -- -- MOLNMolecular Partners AG24.55x -- $787.5K -$19M
-
Which has Higher Returns ZRSEF or NLSP?
NLS Pharmaceutics has a net margin of -- compared to DocMorris AG's net margin of --. DocMorris AG's return on equity of -21.68% beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris AG-- -- $861.7M NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About ZRSEF or NLSP?
DocMorris AG has a consensus price target of --, signalling downside risk potential of --. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 11383.25%. Given that NLS Pharmaceutics has higher upside potential than DocMorris AG, analysts believe NLS Pharmaceutics is more attractive than DocMorris AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris AG0 0 0 NLSPNLS Pharmaceutics0 0 0 -
Is ZRSEF or NLSP More Risky?
DocMorris AG has a beta of 0.064, which suggesting that the stock is 93.601% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZRSEF or NLSP?
DocMorris AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or NLSP?
DocMorris AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. DocMorris AG's net income of -- is lower than NLS Pharmaceutics's net income of --. Notably, DocMorris AG's price-to-earnings ratio is 11.59x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris AG is 0.21x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris AG0.21x 11.59x -- -- NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 21.97% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 6.02% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 0.29% over the past day.
